Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Possible multi bagger here is what could happen
17.65 52 week high, on some positive news this rips folks
We are here an adding, $4 pps is a safe an reasonable target imo
Quad witching for options.
Ocugen, Inc. Announces Issuance of U.S. Patent for Treating Retinal Degenerative Diseases Using ...
MALVERN, Pa., June 13, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ:OCGN), a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel gene and cell therapies, biologicals, and vaccines, today announced that on June 7, 2022, the United States Patent and Trademark Office (“USPTO”) issued U.S. Patent No. 11,351,225, which is directed to methods for preventing or treating an ocular disease or disorder associated with a retinal degenerative disease.
U.S. Patent No. 11,351,225 (the “‘225 Patent”) covers the use of a nuclear hormone receptor gene, such as NR2E3, RORA, NUPR1, and NR2C1, in treating retinal degenerative diseases as well as reducing the risk of developing such diseases. Additional issued claims pertain to using a nuclear hormone receptor gene to treat retinitis pigmentosa, age-related macular degeneration, and inherited retinal degenerative diseases. The ‘225 Patent contains 18 claims and expires in March 2034.
“We are pleased to have been granted this new U.S. patent through our exclusive license agreement with The Schepens Eye Research Institute, an affiliate of Harvard Medical School. We believe this patent significantly validates our modifier gene therapy platform developed by Dr. Neena Haider and augments our growing global patent portfolio,” commented Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen.
This newly allowed patent is exclusive to Ocugen and is the latest U.S. patent issued in connection with Ocugen’s gene therapy program for treating retinal degenerative diseases.
About Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologicals and vaccines that improve health and offer hope for people and global communities. We are making an impact through courageous innovation, taking science in new directions in service of patients. Our breakthrough modifier gene therapy platform has the potential to treat multiple diseases with one drug and we are advancing research in other therapeutic areas to offer new options for people with unmet medical needs. Discover more at www.ocugen.com and follow us on Twitter and LinkedIn.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (“SEC”), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.
Contact
Tiberend Strategic Advisors, Inc.
Jonathan Nugent / Daniel Kontoh-Boateng (Investors)
How much is ocugen paying for postage? I have been getting a piece in the mail every day for two weeks regarding the annual meeting. Today it looks like I’m getting three.
News this morning. Also a related 8k, link here:
FDA hold lifted
https://last10k.com/sec-filings/ocgn/0001104659-22-063664.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=8K&utm_term=ocgn
GO,GO,GO OCGN NOW IN MEXICO!!!HOLDEN THE GOLDEN.
OCGN Definitely NOT a One Trick Pony $$$$
only if you invest now - buy before the NEWS
Been a great swing, flip play here for a couple months.
Congrats...*LOL*. My breakeven is $6.06. Will it reach there at minimum is anybody's guess.
OMG I'm almost even...lol
Plus another block of 11,414,800 @3.72 first trade was red and the last was green..... Ummm????
11.4 MIL @ $3.72, might be a good Monday
14.3 Million @ $3.72 @ close, 1 trade.....OCGN not bad
buy volume is crazy $$$$$$ what a nice dipperrrrrr mhop
I did say 2ss
I'm not mad at today at all I saw it recover nice since the news.
However am I p'ed off that I put more money in at $4 last week to average down heck yea. I wish it was today ... lesson learned hold out for news good or bad. Watch this get Canadian approval the same day the USA denies it. we will be right back at $4 haha where we started <--- no just kidding that won't happen.
i've been trading this for years,seen how and when to grab the opportunities thats all,not in love with any trades
Oh wow, you’re just as delusional as those stocktwit peeps
no shitz,,they have been and still are working on that,look at their pipline meanwhile
Dude, they just got denial EUA for children vaccine. What are you smoking?
buyin the dip,,lol,,they are still working with the fda for children,ocgn has a big pipeline no sweat at these prices,,mhop $$$
Game over for this ticker, EUA denied!
What do you expect to hear?
According to a post in yahoo.finance on the future of Ocugen's Covaxin, Health Canada is said to have said it will undergo accelerated testing of the vaccine.
Am I seeing the beautiful Morning Star Pattern? this show is about to start ...buckle up, get the popcorn and watch the MM's Hedgies and Shorties burn.
The market agrees...so far.
$ocgn offering expected to close this week. Looking forward to recouping the gains we all saw yesterday before the news. $6-8 target exit for me. Hopefully before end of March. Need to move this over to $seed before it takes off
great flipping liquidity....catch it.
loading a few here, flip over $4 near term or better.
Price reset today to equate to the offering share price. Volume is already over 13 million and we arent even 1 hour into the trading day. Hopefully $ocgn will pick back up where it left off yesterday very soon.
And thanks, it's a good name!
Investors taking initial positions during the offering are far better than those who bought an held in the mid range price of 10/12 as you can see, although cost averaging can lower your average pps. If they nail the science on the covid vaccine, i would say a price target of 9/10 is fair based on average sales, imo
Followers
|
225
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
5703
|
Created
|
11/13/15
|
Type
|
Free
|
Moderators sgunderbarth |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |